Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer

被引：18

作者：

Ackroyd S.A. ^{[1
,2
]}

Thomas S. ^{[3
,4
]}

Angel C. ^{[3
,4
]}

Moore R. ^{[3
,4
]}

Meacham P.J. ^{[4
,5
]}

DuBeshter B. ^{[3
,4
]}

机构：

[1] School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

[2] Department of Obstetrics, Gynecology, and Reproductive Sciences, Temple University Hospital, Philadelphia, PA

[3] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY

[4] JP Wilmot Cancer Institute, Rochester, NY

[5] Division of Epidemiology, Department of Public Health Sciences, University of Rochester, Rochester

来源：

Journal of Robotic Surgery | 2018年 / 12卷 / 2期

关键词：

Advanced ovarian cancer; Interval cytoreduction; Neoadjuvant chemotherapy; Robotic surgery;

D O I：

10.1007/s11701-017-0720-2

中图分类号：

学科分类号：

摘要：

The objective of this study is to review our experience with robotic interval cytoreduction following neoadjuvant chemotherapy for advanced ovarian cancer. We retrospectively reviewed patients with advanced ovarian cancer treated with neoadjuvant chemotherapy (NAC) and interval robotic cytoreduction (IRC) between 2011 and 2016 at the University of Rochester Medical Center. Demographic information, chemotherapy treatment, operative results, and follow-up were extracted from medical records. Twenty-nine patients underwent IRC after a mean of 3.9 cycles of NAC. The mean operative time was 165 min with a mean EBL of 107 cc. The mean length of stay was 2.0 days. One case (3.3%) was converted to an open procedure because of extensive tumor not amenable to robotic cytoreduction. Overall, 19 (66%) patients underwent an R0 cytoreduction, 8 (28%) an optimal (<1 cm) cytoreduction, and 2 (7%) a suboptimal cytoreduction. The median overall survival was 39.7 months and median progression-free survival was 21.2 months. Interval robotic cytoreduction following NAC is feasible and may be preferable to open interval cytoreductive surgery, in specific patients, to minimize morbidity and length of hospital stay. © 2017, Springer-Verlag London Ltd.

引用

页码：245 / 250

页数：5

共 14 条

[1]

Global cancer facts & figures, 3rd edn. American Cancer Society, Atlanta, (2015)

[2]

Survival Rates for Ovarian Cancer, by Stage, (2016)

[3]

Griffiths C.T., Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma, Natl Cancer Inst Monogr, 42, pp. 101-104, (1975)

[4]

Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., Kenter G.G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G.C., Pecorelli S., Reed N.S., Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J Med, 363, 10, pp. 943-953, (2010)

[5]

Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T., Luesley D., Perren T., Bannoo S., Mascarenhas M., Dobbs S., Essapen S., Twigg J., Herod J., McCluggage G., Parmar M., Swart A.M., Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 386, 9990, pp. 249-257, (2015)

[6]

Ramirez P.T., Adams S., Boggess J.F., Burke W.M., Frumovitz M.M., Gardner G.J., Havrilesky L.J., Holloway R., Lowe M.P., Magrina J.F., Moore D.H., Soliman P.T., Yap S., Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology’s Clinical Practice Robotics Task Force, Gynecol Oncol, 124, 2, pp. 180-184, (2012)

[7]

Feuer G.A., Lakhi N., Barker J., Salmieri S., Burrell M., Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach, Gynecol Oncol, 131, 3, pp. 520-524, (2013)

[8]

Fader A.N., Rose P.G., Role of surgery in ovarian carcinoma, J Clin Oncol, 25, 20, pp. 2873-2883, (2007)

[9]

Magrina J.F., Zanagnolo V., Noble B.N., Kho R.M., Magtibay P., Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy, Gynecol Oncol, 121, 1, pp. 100-105, (2011)

[10]

Nezhat F.R., Pejovic T., Finger T.N., Khalil S.S., Role of minimally invasive surgery in ovarian cancer, J Minim Invasive Gynecol, 20, 6, pp. 754-765, (2013)

← 1 2 →